Skip to main content


Clinical trials

10-08-2018 | Diabetes prevention | EASD 2018 | Article

Expert commentary: The PREVIEW project

Amrit Lamba considers the rather mixed results of the PREVIEW project, and what they mean for primary care (3:40).

10-05-2018 | Lorcaserin | EASD 2018 | News

Weight loss with lorcaserin linked to improved glycemic profile

Losing weight in the CAMELLIA-TIMI 61 trial was associated with a significantly reduced risk for developing type 2 diabetes, the investigators have reported at the 54th EASD Annual Meeting in Berlin, Germany.

03-12-2018 | Diabetes prevention | News

IL-1 beta inhibition does not prevent diabetes

Interleukin-1 beta inhibition with canakinumab does not prevent the development of type 2 diabetes, a secondary analysis of data from CANTOS shows.

02-28-2018 | Diabetes prevention | Article

Fibre supplementation for the prevention of type 2 diabetes and improvement of glucose metabolism: The randomized controlled Optimal Fibre Trial (OptiFiT)

Honsek C et al. Diabetologia 2018; Advance online publication. doi: 10.1007/s00125-018-4582-6

01-03-2018 | Physical activity | Editorial | Article

Physical activity for health, weight loss, and diabetes prevention and treatment: What should be recommended?

Editorial Board member John Wilding highlights the current evidence for the benefits of physical activity across various domains of type 2 diabetes care and prevention, presenting his view of what should be recommended.

11-06-2017 | Prediabetes | News

Lifestyle interventions have most staying power for diabetes prevention

A meta-analysis shows that although medications and lifestyle changes can both reduce the risk for type 2 diabetes in high-risk patients, only lifestyle modifications have a sustained effect.

02-23-2017 | Liraglutide (obesity) | News

Liraglutide boosts preventive power of lifestyle intervention in prediabetes

Liraglutide enhances the positive effects of lifestyle intervention on weight loss and glycemic control in patients with prediabetes, show the 3-year outcomes of the SCALE Obesity and Prediabetes trial.

Image Credits